Real Life Lipid Management in Hospitals Not Participating in PENELOPE Trial - Control Population for PENELOPE

Launched by CLINICAL OPERATIONS WCN B.V. · Dec 12, 2022

Keywords

ClinConnect Summary

The recent PENELOPE study was designed to determine the effect of a protocolized, Dutch-, and ESC- guideline based strategy of stepwise intensified lipid management in patients at very high risk for ACS. In PENELOPE 22 Dutch non-academic hospitals, members of the WCN investigator network, implemented a protocol guided guideline approach in a consecutive cohort of very high-risk patients admitted for ACS over the period 01-01-2019 to 31-08-2020. Lipid values and medication strategy are collected at baseline (index ACS), and after three months and one year post ACS, in order to establish the ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \>18 and ≤70 years
• • Alive at hospital discharge after admission for (N)STEMI between 1-1-2019 and 31-08-2020
• • Planned for follow-up at a participating PENELOPE CTRL site
• * History of T2DM and/or history of ASCVD defined as either one of:
• • cerebrovascular disease/ event: transient ischemic attack, cerebral infarction, amaurosis fugax, retinal infarction
• • Coronary artery disease/ event: unstable angina pectoris, MI, ACS, coronary revascularization (coronary angioplasty or surgical procedure for coronary bypass)
• • Peripheral artery disease (symptomatic and documented obstruction of a distal extremity artery or surgical intervention (percutaneous transluminal angioplasty, bypass or amputation)
• Exclusion Criteria:
• • Pregnant and lactating women
• • Participation in lipid modifying drug trials up to two years after index cardiovascular event

Trial Officials